This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
Doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma (HCC) Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2012
Hepatocellular carcinoma (HCC) is primary cancer of the liver that accounts for more than 80% of all liver cancer types. Although HCC is uncommon in the United States, there are more than 1 million new cases diagnosed globally each year. HCC is an aggressive tumor that is one of the most common causes of cancer death worldwide. The overall 5-year survival rate for liver cancer is 14%. Signs and symptoms in the early stages of HCC are uncommon. HCC is associated with cirrhosis in 50% to 80% of cases. Hepatitis B and C infections appear to be the most significant causes of HCC. Appropriate treatment for HCC depends upon the stage of disease. Only about 5% of patients are eligible for tumor resection, which is indicated in cases with solitary tumors that are confined to the liver and normal or well-preserved liver function. Patients with localized or locally advanced, unresectable cancer may be treated with liver transplantation, percutaneous radiofrequency ablation, transarterial chemoembolization (TACE), or other forms of ablation. Advanced liver cancer may be treated with TACE, but only in patients who do not have extrahepatic spread of disease.
Subject indexing assigned by CRD
Antibiotics, Antineoplastic; Carcinoma, Hepatocellulars; Chemoembolization, Therapeutic; Doxorubicin; Liver Neoplasms
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: email@example.com
Date abstract record published